试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-06-22
Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia
编号:NCT01760993登记状态:提前终止企业 / 申办者:Shire
药物 / 成分:SPD489
登记的停止原因(原文):Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-06-22
UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
编号:NCT02128230登记状态:提前终止企业 / 申办者:University of Arkansas
药物 / 成分:myPRS、Induction 1 - MEL-10+CFZ-TD-PACE、First Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic)、Inter-Therapy - MEL-20+CFZ-TD-PACE (75%)
登记的停止原因(原文):Low enrollment and Futility as determined by Amgen's Carfilzomib NASCR program.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-06-22
Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors
编号:NCT02168725登记状态:提前终止企业 / 申办者:Traws Pharma, Inc.
药物 / 成分:briciclib
登记的停止原因(原文):The study was placed on hold by the FDA due to manufacturing issues and was not restarted.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-06-22
A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL
编号:NCT02323230登记状态:提前终止企业 / 申办者:ImmunoVaccine Technologies, Inc. (IMV Inc.)
药物 / 成分:DPX-Survivac、Cyclophosphamide
登记的停止原因(原文):new study
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-06-22
Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma
编号:NCT03190213登记状态:提前终止企业 / 申办者:University of Utah
药物 / 成分:Pembrolizumab Injection
登记的停止原因(原文):Update on clinical development: after discussions with the drug manufacturer, the PI has decided to discontinue the trial.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-06-22
Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)
编号:NCT03219866登记状态:提前终止企业 / 申办者:Wake Forest University Health Sciences
药物 / 成分:Nebulizers、Dry Powder Inhaler、Brovana、Pulmicort
登记的停止原因(原文):Lower enrollment than Sponsor expected - Sponsor stopped study
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-06-22
Riociguat in Patients With Operable CTEPH Prior to Pulmonary Endarterectomy (PEA Bridging Study)
编号:NCT03273257登记状态:提前终止企业 / 申办者:International CTEPH Association
药物 / 成分:Riociguat、Placebo、Pulmonary endarterectomy
登记的停止原因(原文):The study was stopped due to slower than expected recruitment and the additional limitations on clinical research imposed by the COVID-19 pandemic, both of which made study completion within a reasonable timeframe appear unlikely.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-06-22
Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis
编号:NCT03410056登记状态:提前终止企业 / 申办者:Amgen
药物 / 成分:Efavaleukin alfa、Placebo
登记的停止原因(原文):Amgen made a business decision not to proceed with Phase 2.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-06-22
Phase I Study of DS-2741a in Healthy Volunteers and Participants With Atopic Dermatitis
编号:NCT04211415登记状态:提前终止企业 / 申办者:Daiichi Sankyo Co., Ltd.
药物 / 成分:DS-2741a、Placebo
登记的停止原因(原文):Company decision of termination of the clinical program.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-06-21
Safety of Intranodal ECI-006 in Melanoma Patients
编号:NCT03394937登记状态:提前终止企业 / 申办者:eTheRNA immunotherapies
药物 / 成分:ECI-006
登记的停止原因(原文):Expiry of study medication
查看官方原始记录 ↗